NeurAxis (NASDAQ:NRXS – Get Free Report) is projected to post its results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $2.00 million for the quarter.
NeurAxis Price Performance
NASDAQ:NRXS traded up $0.29 during mid-day trading on Tuesday, reaching $6.88. The stock had a trading volume of 99,150 shares, compared to its average volume of 137,543. The stock has a market cap of $85.84 million, a P/E ratio of -3.74 and a beta of 1.43. The business’s 50 day moving average is $6.94 and its 200 day moving average is $6.57. NeurAxis has a fifty-two week low of $2.20 and a fifty-two week high of $9.33.
Institutional Investors Weigh In On NeurAxis
Several institutional investors and hedge funds have recently modified their holdings of NRXS. Citadel Advisors LLC raised its holdings in NeurAxis by 39.6% during the third quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock valued at $110,000 after buying an additional 10,103 shares in the last quarter. Manatuck Hill Partners LLC bought a new stake in shares of NeurAxis during the 2nd quarter worth about $122,000. State Street Corp bought a new stake in shares of NeurAxis during the 4th quarter worth about $139,000. Geode Capital Management LLC increased its holdings in shares of NeurAxis by 48.8% during the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock valued at $343,000 after acquiring an additional 24,817 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new position in shares of NeurAxis in the 4th quarter valued at approximately $1,299,000. Institutional investors and hedge funds own 11.77% of the company’s stock.
About NeurAxis
NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.
NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.
Featured Stories
- Five stocks we like better than NeurAxis
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
- Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings Beat
- Marriott’s Earnings Drop May Be Missing the Bigger Fee Growth Story
- Apple’s AI Strategy Looks Different—Will It Pay Off?
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
